Skip to main content
European Commission logo print header

FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.

Project description

New regenerative implant to prevent total knee replacement

Knee cartilage deterioration or injuries are often the cause of osteoarthritis. This chronic disease associated with pain, stiffness and severe disability decreases the quality of life and represents a serious economic burden for health systems. However, existing treatments such as total knee joint replacement are expensive and often involve complications. The EU-funded FibroFix Cartilage project proposes a regenerative orthopaedic implant that addresses the problem of large and/or osteoarthritic articular cartilage lesions in the knee. The silk-based implant is biostable and biocompatible, emulating cartilage function and supporting cartilage regeneration at a significantly lower cost than other solutions. The product allows prolonged use of the joint, increases mobility, reduces pain and postpones or prevents total knee replacement.

Objective

FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.

Cartilage deterioration and injuries often lead to osteoarthritis (OA) – a long-term chronic disease resulting in bones rubbing together and creating pain, stiffness and severe disability. Knee cartilage injuries are very common and almost half of them go on to develop OA, which is second only to heart disease as a cause of work disability. Resulting from decreased quality
of life, hospitalizations and loss of productivity, the economic cost of OA is particularly high in every country that it has been estimated. Currently, all treatments available, including Total Knee joint Replacement (TKR) as the ultimate recourse, are inefficient and expensive: they involve pain, lengthy rehabilitation, frequent complications and high costs. Therefore, given
the increasing prevalence of knee OA, its associated burdens and the drawbacks of all available treatments, it is becoming increasingly important to develop an innovative cost-effective solution to this major public health problem worldwide.

FibroFix™ Cartilage is a well characterised, regenerative orthopaedic repair product to address the unmet and pressing clinical need of large and/or osteoarthritic articular cartilage lesions in the knee, developed by Orthox. It is biostable, biocompatible, emulates cartilage function and supports cartilage regeneration at the minimum cost effectiveness ratio. It allows resurfacing of large and/or potentially OA cartilage lesions, prolonged use of the joint, increased mobility, reduced pain and postponement or prevention of TKR. Smooth, robust, resilient, durable and lubricious, it is a unique combination to be applied in orthopaedics and biomaterials shifting the paradigm in knee OA treatment and up to 10 times less expensive than other solutions.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Coordinator

ORTHOX LIMITED
Net EU contribution
€ 2 496 960,38
Address
66 innovation drive milton park
OX14 4RQ Abingdon
United Kingdom

See on map

Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 1 070 125,87